“With the present report, the DAPT-MVD investigators were able to isolate a unique population with high ischemic risk but low bleeding risk, a 'decoupling of ischemic benefit from hemorrhagic harm.' By strictly selecting patients younger than 75 years of age, who had already received a full year of DAPT without adverse events, they successfully identified a cohort that could reap the atherothrombotic benefits of prolonged P2Y12 inhibition without paying the price of hemorrhage.”
Park et al. (Wed,) studied this question.